Literature DB >> 25931918

Retrohepatic inferior vena cava reconstruction with saphenous vein patch in advanced stage cholangiocarcinoma.

Abuzer Dirican1, Mustafa Özsoy2, Bora Barut1, Volkan İnce1, Mustafa Ateş1, Sezai Yılmaz1.   

Abstract

Hepatic resection is the only known curative treatment option in primary and metastatic liver tumors. Unlike other types of malignancies, the response rate to even the best chemotherapy protocols is quite low in liver malignancies. Survival is expressed in months in untreated liver malignancies or in patients with residual tumor after resection. The optimal survival can be achieved only by liver resection with negative surgical margins. In order to increase the number of patients suitable for hepatic resection, techniques such as portal vein embolization, neoadjuvant chemotherapy, two-step hepatectomy, re-do hepatectomy, hypothermic liver perfusion have been developed and newer modalities are still being investigated. Primary liver malignancies like hepatocellular carcinoma and cholangiocarcinoma, and metastatic liver tumors can invade the retrohepatic vena cava due to anatomical proximity. Invasion of either the hepatocaval confluence or vena cava are often considered as contraindications for liver resection due to the risk of intraoperative massive air embolism or hemorrhage. In this article, we present a patient who underwent left hepatectomy together with vena cava resection and reconstruction with saphenous vein patch due to cholangiocarcinoma.

Entities:  

Keywords:  Cholangiocarcinoma; inferior vena cava resection; liver; resection

Year:  2014        PMID: 25931918      PMCID: PMC4379848          DOI: 10.5152/UCD.2014.2689

Source DB:  PubMed          Journal:  Ulus Cerrahi Derg        ISSN: 1300-0705


  10 in total

1.  Liver resection combined with excision of vena cava.

Authors:  J R Madariaga; J Fung; J Gutierrez; J Bueno; S Iwatsuki
Journal:  J Am Coll Surg       Date:  2000-09       Impact factor: 6.113

2.  Combined liver resection and reconstruction of the supra-renal vena cava: the Paul Brousse experience.

Authors:  Daniel Azoulay; Paola Andreani; Umberto Maggi; Chadi Salloum; Fabiano Perdigao; Mylène Sebagh; Antoinette Lemoine; René Adam; Denis Castaing
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

3.  Ex vivo and in situ resection of inferior vena cava with hepatectomy for colorectal metastases.

Authors:  J P Lodge; B J Ammori; K R Prasad; M C Bellamy
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

4.  Surgical treatment of hilar carcinoma of the bile duct.

Authors:  R Mizumoto; Y Kawarada; H Suzuki
Journal:  Surg Gynecol Obstet       Date:  1986-02

5.  Extensive resection of the bile ducts combined with liver resection for cancer of the main hepatic duct junction: a cooperative study of the Keio Bile Duct Cancer Study Group.

Authors:  Y Sugiura; S Nakamura; S Iida; Y Hosoda; S Ikeuchi; S Mori; A Sugioka; T Tsuzuki
Journal:  Surgery       Date:  1994-04       Impact factor: 3.982

Review 6.  Diagnostic and surgical approaches in hilar cholangiocarcinoma.

Authors:  Gerd Otto
Journal:  Int J Colorectal Dis       Date:  2006-03-31       Impact factor: 2.571

Review 7.  Hepatocellular carcinoma: current surgical management.

Authors:  Tae-Jin Song; Edmund Wai Kit Ip; Yuman Fong
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

8.  Inferior vena cava resection with hepatectomy: challenging but justified.

Authors:  Deep J Malde; Aamir Khan; K Rajendra Prasad; Giles J Toogood; J Peter A Lodge
Journal:  HPB (Oxford)       Date:  2011-09-16       Impact factor: 3.647

9.  Significance of hepatic resection combined with inferior vena cava resection and its reconstruction with expanded polytetrafluoroethylene for treatment of liver tumors.

Authors:  Shigeki Arii; Kennichi Teramoto; Toru Kawamura; Susumu Takamatsu; Eigo Sato; Noriaki Nakamura; Takahisa Iwai; Akira Mori; Junji Tanaka; Masayaki Imamura
Journal:  J Am Coll Surg       Date:  2003-02       Impact factor: 6.113

Review 10.  Current surgical treatment for bile duct cancer.

Authors:  Yasuji Seyama; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.